{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:07:25Z","timestamp":1776406045380,"version":"3.51.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Key Research and Development Project of the Science & Technology Department of Sichuan Province","award":["2022YFS0625"],"award-info":[{"award-number":["2022YFS0625"]}]},{"name":"Luzhou science and technology bureau science and technology innovation research and development project","award":["2023CDLZ-17"],"award-info":[{"award-number":["2023CDLZ-17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00228-026-04031-9","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T03:32:50Z","timestamp":1775014370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review and first meta-analysis of the efficacy and safety of gemcitabine-cisplatin combined with paclitaxel in patients with advanced biliary tract cancer"],"prefix":"10.1007","volume":"82","author":[{"given":"Gang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenglan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoying","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangnian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanli","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"4031_CR1","doi-asserted-by":"publisher","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A, Valle JW, Ducreux M & ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2023). Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals oncology: official J Eur Soc Med Oncol, 34(2), 127\u2013140. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506","DOI":"10.1016\/j.annonc.2022.10.506"},{"issue":"2","key":"4031_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. Cancer J Clin 73(2):198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759","journal-title":"Cancer J Clin"},{"issue":"1","key":"4031_CR3","doi-asserted-by":"publisher","first-page":"100378","DOI":"10.1016\/j.esmoop.2021.100378","volume":"7","author":"A Lamarca","year":"2022","unstructured":"Lamarca A, Edeline J, Goyal L (2022) How I treat biliary tract cancer. ESMO open 7(1):100378. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100378","journal-title":"ESMO open"},{"issue":"14","key":"4031_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"issue":"1","key":"4031_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-017-3353-2","volume":"80","author":"BJ Kim","year":"2017","unstructured":"Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Cho H, Ryoo BY, Chang HM (2017) Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol 80(1):209\u2013215. https:\/\/doi.org\/10.1007\/s00280-017-3353-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4031_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/annonc\/mdt540","volume":"25","author":"JW Valle","year":"2014","unstructured":"Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J, Okusaka T (2014) Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Annals oncology: official J Eur Soc Med Oncol 25(2):391\u2013398. https:\/\/doi.org\/10.1093\/annonc\/mdt540","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"8","key":"4031_CR7","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, He R, Qin A, Chen S, Okusaka LT, Vogel T, Kim A, Suksombooncharoen JW, Lee TA, Kitano M, Burris M, Bouattour H, Tanasanvimon M, McNamara S, Zaucha MG, Avallone R, Tan A, Cundom B, Lee J, Takahashi CK, Valle H, J. W (2022) Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid 1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evid"},{"issue":"10391","key":"4031_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Kl\u00fcmpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, KEYNOTE-966 Investigators (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England) 401(10391):1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet (London England)"},{"issue":"34","key":"4031_CR9","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin oncology: official J Am Soc Clin Oncol 29(34):4548\u20134554. https:\/\/doi.org\/10.1200\/JCO.2011.36.5742","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"31","key":"4031_CR10","doi-asserted-by":"publisher","first-page":"50624","DOI":"10.18632\/oncotarget.9562","volume":"7","author":"Y Fan","year":"2016","unstructured":"Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, Gong L, Yu H, Yang H, Liu J, Lei T, Zhao Q, Mao W (2016) Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget 7(31):50624\u201350634. https:\/\/doi.org\/10.18632\/oncotarget.9562","journal-title":"Oncotarget"},{"issue":"3","key":"4031_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00280-023-04512-z","volume":"91","author":"LAW de Jong","year":"2023","unstructured":"de Jong LAW, Lambert M, van Erp NP, de Vries L, Chatelut E, Ottevanger PB (2023) Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer Chemother Pharmacol 91(3):247\u2013256. https:\/\/doi.org\/10.1007\/s00280-023-04512-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4031_CR12","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1038\/s41467-022-31704-7","volume":"13","author":"B Wang","year":"2022","unstructured":"Wang B, Sun T, Zhao Y, Wang S, Zhang J, Wang Z, Teng YE, Cai L, Yan M, Wang X, Jiang Z, Pan Y, Luo J, Shao Z, Wu J, Guo X, Hu X (2022) A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nat Commun 13(1):4025. https:\/\/doi.org\/10.1038\/s41467-022-31704-7","journal-title":"Nat Commun"},{"issue":"5","key":"4031_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/1078-0432.CCR-24-3321","volume":"31","author":"Y Qie","year":"2025","unstructured":"Qie Y, Huang S, Shen C, Wu Z, Da L, Jia K, Zhang Z, Zhao G, Wang L, Xu G, Zhao Y, Liang R, Guo J, Li C, Dong H, Li M, Li H, Chen H, Tian D, Wu C, Hu H (2025) Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High-Risk Non-Muscle-Invasive Bladder Cancer. Clin cancer research: official J Am Association Cancer Res 31(5):839\u2013847. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3321","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"4031_CR14","doi-asserted-by":"publisher","first-page":"175883592312250","DOI":"10.1177\/17588359231225045","volume":"16","author":"JH Choi","year":"2024","unstructured":"Choi JH, Park H, Park JK, Lee JK, Lee KT, Lee KH (2024) Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers. Therapeutic Adv Med Oncol 16:17588359231225045. https:\/\/doi.org\/10.1177\/17588359231225045","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"5","key":"4031_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO-24-01383","volume":"43","author":"RT Shroff","year":"2025","unstructured":"Shroff RT, King G, Colby S, Scott AJ, Borad MJ, Goff L, Matin K, Mahipal A, Kalyan A, Javle MM, Dika E, Tan I, Cheema B, Patel P, Iyer A, Kelley R, Thumar RK, El-Khoueiry J, Guthrie A, Chiorean KA, Philip EG, P. A (2025) SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. J Clin oncology: official J Am Soc Clin Oncol 43(5):536\u2013544. https:\/\/doi.org\/10.1200\/JCO-24-01383","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"7","key":"4031_CR16","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"issue":"10","key":"4031_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jclinepi.2008.10.009","volume":"62","author":"BJ Shea","year":"2009","unstructured":"Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M (2009) AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62(10):1013\u20131020. https:\/\/doi.org\/10.1016\/j.jclinepi.2008.10.009","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4031_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13643-025-02752-z","volume":"14","author":"JF Tierney","year":"2025","unstructured":"Tierney JF, Burdett S, Fisher DJ (2025) Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance. Syst reviews 14(1):84. https:\/\/doi.org\/10.1186\/s13643-025-02752-z","journal-title":"Syst reviews"},{"issue":"2","key":"4031_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.surg.2022.09.028","volume":"173","author":"SH Choi","year":"2023","unstructured":"Choi SH, Kang I, Lee SH, Kang B, Cheon J, Kim DJ, Kim G, Kwon CI, Ko KH, Chon HJ (2023) Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Surgery 173(2):280\u2013288. https:\/\/doi.org\/10.1016\/j.surg.2022.09.028","journal-title":"Surgery"},{"key":"4031_CR20","doi-asserted-by":"publisher","first-page":"175883592110359","DOI":"10.1177\/17588359211035983","volume":"13","author":"J Cheon","year":"2021","unstructured":"Cheon J, Lee CK, Sang YB, Choi HJ, Kim MH, Ji JH, Ko KH, Kwon CI, Kim DJ, Choi SH, Kim C, Kang B, Chon HJ (2021) Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis. Therapeutic Adv Med Oncol 13:17588359211035983. https:\/\/doi.org\/10.1177\/17588359211035983","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"1","key":"4031_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12029-023-00946-z","volume":"55","author":"S Gedela","year":"2024","unstructured":"Gedela S, Munot P, Vaidyanathan A, Joarder R, Chaugule D, Parulekar M, Nashikkar C, Ghadi A, Vadodaria D, Goel M, Patkar S, Mandavkar S, Ramaswamy A, Bhargava P, Srinivas S, Ostwal V (2024) Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers. J Gastrointest cancer 55(1):263\u2013269. https:\/\/doi.org\/10.1007\/s12029-023-00946-z","journal-title":"J Gastrointest cancer"},{"issue":"6","key":"4031_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ (2019) Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol 5(6):824\u2013830. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0270","journal-title":"JAMA Oncol"},{"issue":"2","key":"4031_CR23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.4143\/crt.2023.726","volume":"56","author":"T Liu","year":"2024","unstructured":"Liu T, Li Q, Lin Z, Liu C, Pu W, Zeng S, Lai J, Cai X, Zhang L, Wang S, Chen M, Cao W, Gou H, Zhu Q (2024) A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer. Cancer Res Treat 56(2):602\u2013615. https:\/\/doi.org\/10.4143\/crt.2023.726","journal-title":"Cancer Res Treat"},{"key":"4031_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001650","author":"S Woo","year":"2025","unstructured":"Woo S, Kang B, Lee SH, Kim JS, Kang H, Yang SJ, An C, Kim G, Jo GH, Kwon CI, Sung MJ, Shin SP, Jung S, Hwang S, Kim C, Chon HJ (2025) Biology-driven stratification of advanced biliary tract cancer treated with nab-paclitaxel plus gemcitabine-cisplatin: A prospective observational cohort study. Hepatology (Baltimore MD). https:\/\/doi.org\/10.1097\/HEP.0000000000001650Advance online publication","journal-title":"Hepatology (Baltimore MD)"},{"issue":"10","key":"4031_CR25","doi-asserted-by":"publisher","first-page":"e2534560","DOI":"10.1001\/jamanetworkopen.2025.34560","volume":"8","author":"H Jeong","year":"2025","unstructured":"Jeong H, Yoo C, Kim I, Kang JH, Jeong JH, Park K, Oh SB, Park I, Sym SJ, Cheon J, Ryu H, Hwang JE, Lee JS, Ryoo BY, Kim KP (2025) Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial. JAMA Netw open 8(10):e2534560. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.34560","journal-title":"JAMA Netw open"},{"issue":"5","key":"4031_CR26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.5009\/gnl210346","volume":"16","author":"K Jung","year":"2022","unstructured":"Jung K, Park J, Jung JH, Lee JC, Kim J, Hwang JH (2022) Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis. Gut Liver 16(5):798\u2013805. https:\/\/doi.org\/10.5009\/gnl210346","journal-title":"Gut Liver"},{"issue":"2","key":"4031_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J cancer (Oxford England: 1990) 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"4","key":"4031_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103(4):469\u2013474. https:\/\/doi.org\/10.1038\/sj.bjc.6605779","journal-title":"Br J Cancer"},{"issue":"3","key":"4031_CR29","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.jhepr.2024.101290","volume":"7","author":"Z Li","year":"2024","unstructured":"Li Z, Aliseda D, Jones O, Rajendran L, Magyar C, Grant R, O\u2019Kane GM, Saborowski A, Sapisochin G, Vogel A (2024) Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis using reconstructed RCT survival data. JHEP reports: Innov Hepatol 7(3):101290. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101290","journal-title":"JHEP reports: Innov Hepatol"},{"issue":"10272","key":"4031_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX (2021) Biliary tract cancer. Lancet (London England) 397(10272):428\u2013444. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7","journal-title":"Lancet (London England)"},{"issue":"8","key":"4031_CR31","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, Valle JW (2024) Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. lancet Gastroenterol Hepatol 9(8):694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5","journal-title":"lancet Gastroenterol Hepatol"},{"issue":"1","key":"4031_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3892\/ol.2018.8690","volume":"16","author":"PM Chang","year":"2018","unstructured":"Chang PM, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Liu CY, Chen MH, Chen MH, Yeh CN (2018) Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. Oncol Lett 16(1):566\u2013572. https:\/\/doi.org\/10.3892\/ol.2018.8690","journal-title":"Oncol Lett"},{"issue":"4","key":"4031_CR33","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin cancer research: official J Am Association Cancer Res 12(4):1317\u20131324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1634","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"11","key":"4031_CR34","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","volume":"11","author":"A Sparreboom","year":"2005","unstructured":"Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin cancer research: official J Am Association Cancer Res 11(11):4136\u20134143. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2291","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"4","key":"4031_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253\u2013265. https:\/\/doi.org\/10.1038\/nrc1317","journal-title":"Nat Rev Cancer"},{"key":"4031_CR36","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2025.1019","author":"D Kim","year":"2025","unstructured":"Kim D, Sim NS, Woo S, Kim MH, Lee CK, Hong SS, Kim SH, Hwang HK, Kang CM, Lee WJ, Jo JH, Chung T, Hwang S, Kang B, Kim JS, Kwon CI, Kim S, Chon HJ, Kim CG, Park YN, Choi HJ (2025) Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer. Clin Mol Hepatol. https:\/\/doi.org\/10.3350\/cmh.2025.1019Advance online publication","journal-title":"Clin Mol Hepatol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04031-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04031-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04031-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:37:26Z","timestamp":1776404246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04031-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4031"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04031-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article or claim its manufacturer may make that the publisher does not guarantee or endorse.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s note"}}],"article-number":"111"}}